Eagle Pharmaceuticals Statistics Share Statistics Eagle Pharmaceuticals has 12.96M
shares outstanding. The number of shares has increased by -0.22%
in one year.
Shares Outstanding 12.96M Shares Change (YoY) -0.22% Shares Change (QoQ) 0% Owned by Institutions (%) 0.6% Shares Floating 9.31M Failed to Deliver (FTD) Shares 273 FTD / Avg. Volume 3.51%
Short Selling Information The latest short interest is 350.53K, so undefined% of the outstanding
shares have been sold short.
Short Interest 350.53K Short % of Shares Out n/a Short % of Float 5.59% Short Ratio (days to cover) 3.91
Valuation Ratios PE Ratio 0 Forward PE 0.23 PS Ratio 0 Forward PS n/a PB Ratio 0 P/FCF Ratio 0 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Eagle Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position Current Ratio 0 Quick Ratio 0 Debt / Equity 0 Debt / EBITDA 0.87 Debt / FCF 2.2 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $2.36M Profits Per Employee $265.99K Employee Count 134 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 25.79M Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -71.21% in the
last 52 weeks. The beta is 0.83, so Eagle Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.83 52-Week Price Change -71.21% 50-Day Moving Average 1.14 200-Day Moving Average 2.31 Relative Strength Index (RSI) 58.61 Average Volume (20 Days) 7,783
Income Statement In the last 12 months, Eagle Pharmaceuticals had revenue of 316.61M
and earned 35.64M
in profits. Earnings per share was 2.76.
Revenue 316.61M Gross Profit 221.67M Operating Income 80.96M Net Income 35.64M EBITDA 77.5M EBIT 65.48M Earnings Per Share (EPS) 2.76
Full Income Statement Balance Sheet The company has 55.32M in cash and 67.79M in
debt, giving a net cash position of -12.47M.
Cash & Cash Equivalents 55.32M Total Debt 67.79M Net Cash -12.47M Retained Earnings 111.5M Total Assets 404.82M Working Capital 100.62M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 30.8M
and capital expenditures 0, giving a free cash flow of 30.8M.
Operating Cash Flow 30.8M Capital Expenditures n/a Free Cash Flow 30.8M FCF Per Share 0
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin 25.57% FCF Margin 9.73%
